Apexion Health Semaglutide treatment vial
WEIGHT LOSSGLP-1

MONTHLY SUPPLY · 2.5MG–10MG

SEMAGLUTIDE

TREATMENT

Physician-supervised GLP-1 weight loss

SUPPORT

Semaglutide mimics the GLP-1 hormone to suppress appetite and slow digestion. Clinical trials showed an average 15% reduction in body weight with ongoing physician management.

Shop Now

Lab-Tested · Physician-Supervised · Discreet Delivery

Apexion Health — WEIGHT LOSS

WEIGHT LOSS, GUIDED BY YOUR OWN BIOLOGY.

GLP-1 is a hormone your gut releases after eating. Semaglutide mimics it — signaling fullness to the brain and slowing gastric emptying. Clinical trials demonstrated a mean body weight reduction of approximately 15% over 68 weeks. For patients who have not responded to diet alone, it reframes the conversation entirely.

Clinical Benefits

SEMAGLUTIDE SUPPORTS YOUR HEALTH AT THE CELLULAR LEVEL

  1. 01.

    SHOWN TO REDUCE BODY WEIGHT BY AN AVERAGE OF 15% IN CLINICAL TRIALS

  2. 02.

    SUPPRESSES APPETITE AT THE HYPOTHALAMIC LEVEL

  3. 03.

    SLOWS GASTRIC EMPTYING FOR SUSTAINED FULLNESS

  4. 04.

    SUPPORTS BETTER BLOOD SUGAR REGULATION

  5. 05.

    PHYSICIAN-MONITORED WITH WEEKLY DOSING

  6. 06.

    COMPOUNDED FORMULATION — NO PHARMACY WAITLIST

Shop Now

Clinical Evidence

How It Works in the Body

01 — Dose & Efficacy

STEP 1: Weight Loss at 68 Weeks

≥10% WL 69.1% achieved69%
≥15% WL 50.5% achieved51%
≥5% WL 86.4% achieved86%

Wilding et al., NEJM 2021;384(11):989–1002

02 — Hormone Panel

Cardiometabolic Biomarkers

MarkerWithoutWith Treatment
Waist Circ.cm
115.0
101.5−13.5
HbA1c%
5.4
5.1−0.31
Systolic BPmmHg
128.0
122.9−5.1
CRP (median)mg/L
5.0
2.8−43.5%

Broad cardiometabolic improvement

CRP fell 43.5%, triglycerides 12.7%, HDL rose 5.2%. All measured risk factors improved vs placebo (p<0.001).

Wilding et al., NEJM 2021;384(11):989–1002

03 — Protocol

Dose Escalation Protocol

InitiationWeeks 1–4
  • ›Start 0.25 mg SC weekly
  • ›GI tolerance check
  • ›Weight & waist baseline
EscalationWeeks 5–16
  • ›0.5 → 1.0 → 1.7 mg
  • ›Step up every 4 weeks
  • ›Monitor GI symptoms
MaintenanceWeek 17+
  • ›2.4 mg SC weekly
  • ›Weight q3 months
  • ›HbA1c & metabolic q6 months

Slow titration minimizes GI side effects

Each dose step maintained 4 weeks. Nausea peaks during escalation, typically resolves. Discontinuation due to GI events: 4.5% vs 0.8% placebo.

All protocols physician-supervised and adjusted per individual labs.